An interventional study of CaMaPi and TAU in Self-harm and Suicidal Ideation, sponsored by Nottingham Trent University. Not yet recruiting. Open to participants aged 16 Years to 24 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-06-03.
Sponsored by Nottingham Trent University · Not applicable, Interventional, and Treatment
Suicide and self-harm are global disease burden that contributes significantly to years of lost life and mortality.
Self-harm and suicidal ideation represent a significant global public health concern (Knipe et al., 2022), affecting about 14.6 million people yearly (Nichols et al., 2021). Globally, over 700 000 people die by suicide annually (World Health Organization -- WHO, 2023).
Suicide is the fourth leading cause of death among 15-29-year-olds, and 77% of global suicides occur in low- and middle-income countries, including Nigeria (WHO, 2023). The psychological impact of suicidal ideation includes continuing high tendencies of self-harm (Jidong et al., 2024).
Despite the increasing rates of suicide and self-harm in Nigeria, this topic is understudied, with no culturally appropriate or sustainable psychological interventions.
515 studies on the registry are indexed under Suicidal Ideation; 195 are open to participants now.
This study's planned enrollment of 32 is below the median of 80 across 426 interventional studies indexed under Suicidal Ideation.
Browse Suicidal Ideation studies →Nottingham Trent University is the lead sponsor of 28 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Behavioral: CaMaPi
Other: TAU
CaMaPi is a manually assisted brief psychological intervention that is based on the principles of Cognitive Behaviour Therapy (CBT). The intervention includes psycho-education and a comprehensive cognitive behavioural assessment of the suicidal ideation and self-harm attempt using virtual stories of four young people to be delivered in 8-10 sessions for over three months
Treatment as Usual (TAU) is routine care, such as diagnosis, assessment, psychotherapy, monitoring and any form of intervention (e.g., medication prescription) available at the collaborating service.
Change in acceptance and satisfaction with the intervention
Primary outcome measure would be assessed using the Service Satisfaction Scale
Time frame: Change is being assessed from baseline, end of intervention at 12 weeks, and at 12 weeks post-intervention
Change in suicidal ideation
Secondary outcome measure would be assessed using the Beck Scale for Suicide Ideation
Time frame: Change is being assessed from baseline, end of intervention at 12 weeks, and at 12 weeks post-intervention
Change in hopelessness
Secondary outcome measure would be assessed using the Beck Hopelessness Scale
Time frame: Change is being assessed from baseline, end of intervention at 12 weeks, and at 12 weeks post-intervention
Change in Health Status
Secondary outcome measure would be assessed using the EQ-5D-5L quality of health scale
Time frame: Change is being assessed from baseline, end of intervention at 12 weeks, and at 12 weeks post-intervention
Change in repetition rate's of self-harm
Secondary outcome measure would be assessed using an adapted Suicide Attempt Self-Injury Interview
Time frame: Change is being assessed from baseline, end of intervention at 12 weeks, and at 12 weeks post-intervention
Change in use of health services
Secondary outcome measure would be assessed using Client Service Receipt Inventory
Time frame: Change is being assessed from baseline, end of intervention at 12 weeks, and at 12 weeks post-intervention
Change in psychological distress
Secondary outcome measure would be assessed using Kessler Psychological Distress Scale
Time frame: Change is being assessed from baseline, end of intervention at 12 weeks, and at 12 weeks post-intervention
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nottingham Trent University